Actinium Pharmaceuticals, Inc. 8-K

What Happened Actinium Pharmaceuticals, Inc. filed an 8‑K (Item 8.01) on June 18, 2026, submitting a compliance plan to NYSE American. This follows a May 27, 2026 notice from the exchange that the company was not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide because it failed to meet the stockholders’ equity requirement given reported losses in three of its four most recent fiscal years. The compliance plan outlines actions management intends to take to restore compliance; the 8‑K does not provide further specifics about those actions or timing.

Key Details

• Filing date: June 18, 2026 (8‑K, Item 8.01).
• Prior notice from NYSE American: May 27, 2026, citing non‑compliance with continued listing standards.
• Relevant rule: Section 1003(a)(ii) requires a listed company to maintain stockholders’ equity of $4.0 million or more if it reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
• The company submitted a compliance plan describing intended actions but disclosed no detailed measures or timeline in the 8‑K.

Why It Matters This filing addresses a formal NYSE American notice about Actinium’s failure to meet a minimum stockholders’ equity requirement tied to its recent loss history. For investors, the item is a signal to monitor future company disclosures and any NYSE communications for details of the remediation plan and whether the company regains compliance, since listing status and investor perception can be affected by ongoing non‑compliance updates.